Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

By Lee Sung   Suh Cheolwon   Kim Bong-Seog   Chung Jooseop   Joo Young-Don   Ryoo Hun-Mo   Do Young   Jin Jong-Youl   Kang Hye   Lee Gyeong-Won   Lee Moon   Shim Hyeok   Kim Kihyun   Yoon Sung-Soo   Bang Soo   Kim Ho   Lee Je-Jung   Park Jinny   Lee Dong   Lee Jae-Hoon  

Annals of Hematology, Vol. 89, Iss. 9, 2010-09 ,pp. : 905-912

Springer Publishing Company

Access to resources Recommend Favorite

Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma

By Wang M.   Giralt S.   Delasalle K.   Handy B.   Alexanian R.  

Hematology, Vol. 12, Iss. 3, 2007-06 ,pp. : 235-239

Maney Publishing

Access to resources Recommend Favorite

Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: The role of albumin in the model

By Mihou Dimitra   Katodritou Eirini   Zervas Kostas  

Hematology, Vol. 12, Iss. 6, 2007-12 ,pp. : 527-531

Maney Publishing

Access to resources Recommend Favorite

The effect of the combination of bisphosphonates and conventional chemotherapy on bone metabolic markers in multiple myeloma patients

By Zhang Xi   Chang Chunkang   Zhao Youshan   Wu Lingyun   Zhang Zheng   Li Xiao  

Hematology, Vol. 17, Iss. 5, 2012-09 ,pp. : 255-260

Maney Publishing

Access to resources Recommend Favorite

Immunomodulatory drugs in multiple myeloma

By Andhavarapu Swati   Roy Vivek  

Expert Review of Hematology, Vol. 6, Iss. 1, 2013-02 ,pp. : 69-82

Informa Healthcare

Access to resources Recommend Favorite